Needle-Free Drug Delivery Devices Market Report 2026

The needle-free drug delivery devices market size has grown rapidly in recent years. It will grow from $18.54 billion in 2025 to $20.65 billion in 2026 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to needle phobia among patients, demand for safer injection alternatives, rise in infectious disease vaccinations, limitations of traditional needle-based methods, early advancements in jet injection mechanisms.

The needle-free drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $29.91 billion in 2030 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to increasing chronic disease prevalence, growing adoption of self-administration therapies, expansion of telemedicine and remote care, rising demand for minimally invasive drug delivery, advancements in microneedle and transdermal technologies. Major trends in the forecast period include growing demand for painless drug delivery methods, increasing adoption of home-based drug delivery solutions, rising use of needle-free devices in pediatric applications, growth in self-administration treatments for chronic diseases, expansion of needle-free vaccine delivery systems.

The rising prevalence of diabetes is expected to drive the growth of the needle-free drug delivery devices market. Diabetes, a chronic condition marked by elevated blood sugar levels due to insufficient insulin production or ineffective insulin utilization, is increasing globally due to sedentary lifestyles, unhealthy diets, genetic predisposition, urbanization, aging populations, limited healthcare access, and rising obesity rates. Needle-free drug delivery devices, such as jet injectors and transdermal patches, provide an alternative for insulin administration, reducing injection-related pain and anxiety while improving patient comfort and adherence. For instance, in June 2024, the National Health Service (NHS) in the UK reported that over 549,000 additional individuals in England were at risk of developing type 2 diabetes in 2023, bringing the total pre-diabetic population registered with a GP to 3,615,330 - a nearly 20% increase compared to 2022. Therefore, the increasing prevalence of diabetes is driving the needle-free drug delivery devices market.

Major companies in the needle-free drug delivery device market are increasingly focusing on advanced solutions such as dual-chamber inhalers to improve treatment efficacy and ease of use while addressing the evolving needs of patients and healthcare providers. A dual-chamber inhaler features two separate compartments for holding different medications, enabling the combination of multiple drugs in a single device, streamlining therapy, and enhancing patient convenience. For example, in April 2024, Berry Global, a US-based plastics manufacturer, launched the BerryHaler, an innovative dry powder inhaler (DPI) designed for patient-centered care. The device includes a dual-chamber system, a dose counter for precise medication tracking, an all-plastic construction free of metal parts suitable for complex inhalation therapies, and a bi-directional mouthpiece cover for hygiene and ease of use. Additionally, audible signals help ensure proper administration, while the integrated dose counter enables accurate monitoring, reducing the risk of dosage errors and improving treatment adherence.

In November 2025, Harrow IP LLC, a US-based provider of ophthalmic disease management solutions, acquired Melt Pharmaceuticals for an undisclosed amount. Through this acquisition, Harrow seeks to expand its offerings into the needle-free procedural sedation market by incorporating Melt’s non-opioid, non-intravenous sublingual sedation therapies. This move strengthens Harrow’s presence across hospital, outpatient, and office-based procedural care settings. Melt Pharmaceuticals is a US-based company specializing in innovative sublingual, needle-free sedation solutions.

Major companies operating in the needle-free drug delivery devices market are 3M Company, Medtronic plc, Novo Nordisk AS, Becton Dickinson and Company, Insulet Corporation, MannKind Corporation, Med-Jet Inc., Portal Instruments, PharmaJet, National Medical Products Inc., Mika Medical Co. Ltd., Medical International Technology Inc. (MTI), NanoPass Technologies Ltd., PenJet Corporation, Akra Dermojet S.A., NuGen Medical Devices Inc., Crossject SA, Injex Pharma AG, Bayer AG, Antares Pharma Inc., Inovio Pharmaceuticals Inc.

North America was the largest region in the needle-free drug delivery devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the needle-free drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the needle-free drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on medical devices, electronic components, and raw materials used in manufacturing needle-free drug delivery technologies have increased production and supply chain costs, particularly affecting regions dependent on imports such as North America and Europe. Segments like jet injectors and transdermal patch systems face the highest impact due to specialized components. However, tariffs can encourage local manufacturing expansion, stimulate domestic innovation, and reduce import dependency over time, offering potential long-term benefits.

The needle-free drug delivery devices market research report is one of a series of new reports that provides needle-free drug delivery devices market statistics, including needle-free drug delivery devices industry global market size, regional shares, competitors with a needle-free drug delivery devices market share, detailed needle-free drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the needle-free drug delivery devices industry. This needle-free drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Needle-free drug delivery devices are medical tools designed to administer medications without the use of traditional needles. They provide an alternative method for delivering drugs, vaccines, or therapeutic agents through the skin or mucosal membranes, aiming to reduce patient discomfort and minimize the risk of needle-related injuries.

The main types of needle-free drug delivery devices include inhalers, jet injectors, novel needles, transdermal patches, and others. Inhalers are portable devices that deliver medication directly into the lungs as a mist or spray. These devices are used for various applications, including pain management, vaccine delivery, pediatric injections, insulin administration, and more, by end users such as hospitals, clinics, and home healthcare providers.

The needle-free drug delivery devices market consists of sales of nasal sprays, buccal patches, and oral inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.